Alfred Ian Lee MD, PhD

Assistant Professor of Medicine (Hematology); Firm Chief, Inpatient Hematology, Yale Cancer Center; Assistant Program Director, Traditional Internal Medicine Residency Program

Clinical Interests

Lymphoma; platelet disorders; thrombosis; bleeding; coagulation disorders; leukemia


Board Certifications

2013
Hematology, Internal Medicine, Board Certified
2007
Internal Medicine, Board Certified

Patient Care Locations

 
alfred_leefaculty-clinicsfalsetruetrue6truefalsefalse
 

Clinical Trials

Conditions Study Title
Hepatic Veno-Occlusive Disease, Hodgkin's Lymphoma, Leukemia, not otherwise specified, Multiple Myeloma, and Non-Hodgkin's Lymphoma Defibrotide for Patients with Hepatic Veno-Occlusive Disease (VOD): A Treatment IND Study
Hemophilia A An ascending single dose study to evaluate the safety, tolerability and pharmacokinetics/pharmacodynamics of PF-05280602, a recombinant factor VIIa variant (813D), in adult hemophilia A and B subjects with or without inhibitors.
Antiphospholipid Syndrome (APS) Comparison of Gut Commensal Bacteria Between Persistently anti-gamma2 Glycoprotein-I Positive Patients and Antiphospholipid Antibody Negative Patients
Ill-Defined Sites and Unknown Sites A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises
Non-Hodgkin's Lymphoma A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30- positive mature T-cell lymphomas

More Clinical Trials...

Edit Profile